 We welcome that, but what I will tell you is the conversation cannot be limited to those two entities. We have to bring in the provider community, and that includes pharmacies, physicians, hospitals, healthcare systems. It actually includes society and policymakers as well. I think, as we've heard, what's the debate been for the last 20 years? How to lower drug costs, not how to stabilize and potentially increase drug costs in the generic industry or anywhere else.